Trials / Completed

CompletedNCT06558084

Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy

Status: Completed
Phase: —
Study type: Observational
Enrollment: 64 (actual)

Sponsor: Ain Shams University · Academic / Other
Sex: Female
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To assess CDK4/6i toxicity and effect on PFS in the Egyptian population

Conditions

Toxicity, Drug
Progression, Disease

Interventions

Type	Name	Description
DRUG	CDK4/6 Inhibitor	CDK4/6 inhibitor in first and second lines

Timeline

Start date: 2022-07-06
Primary completion: 2024-07-31
Completion: 2024-08-10
First posted: 2024-08-16
Last updated: 2024-08-16

Locations

1 site across 1 country: Egypt

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06558084. Inclusion in this directory is not an endorsement.